(NASDAQ: MIST) Milestone Pharmaceuticals's forecast annual revenue growth rate of 304.84% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.42%.
Milestone Pharmaceuticals's revenue in 2026 is $1,784,000.On average, 8 Wall Street analysts forecast MIST's revenue for 2026 to be $900,742,885, with the lowest MIST revenue forecast at $488,032,082, and the highest MIST revenue forecast at $1,307,228,790. On average, 8 Wall Street analysts forecast MIST's revenue for 2027 to be $3,739,794,821, with the lowest MIST revenue forecast at $2,562,168,428, and the highest MIST revenue forecast at $5,228,915,160.
In 2028, MIST is forecast to generate $16,911,805,603 in revenue, with the lowest revenue forecast at $6,954,457,163 and the highest revenue forecast at $37,412,887,970.